



Announcement of New Appointments

Tokyo –27 February 2009 – Sosei Group Corporation (“Sosei”; TSE, Mothers Index: 4565), a biopharmaceutical company, is pleased to announce the following new appointment.

Akinori Mochizuki Ph.D.

Appointed as Representative Executive Officer and R&D Planning Director of Sosei R&D Ltd.

Effective immediately, Dr Akinori Mochizuki will lead the company’s research and development and join the executive management team.

- End -

Notes to editors:

Akinori Mochizuki Ph.D.

Dr Akinori Mochizuki joined Sosei in 2004 to lead the Company's discovery efforts. In 2008, he was appointed R&D Planning Director. Prior to joining Sosei, he was a research fellow at the Respiratory Cell and Molecular Biology (RCMB) of Southampton General Hospital, University of Southampton, UK.

For further information please contact:

Sosei Group Corporation

Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan

Hidetoshi TORAMI, Director of Administration

E-mail : htorami@sosei.com Tel: +81-3-5210-3290 Fax: +81-3-5210-3291

1F London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH

Non OSAKABE, PA to CEO

E-mail: nosakabe@sosei.com Tel: +44-20-7691-2081 Fax: +44-20-7209-2484

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model based primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit www.osei.com